Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience
Gile, Jennifer , Ou, Fang‐Shu , Mahipal, Amit , Larson, Joseph J. , Mody, Kabir , Jin, Zhaohui , Hubbard, Joleen M. , Hálfdánarson, Þorvarður R. , Alberts, Steven R. , Jatoi, Aminah , Smoot, Rory L. , Roberts, Lewis R. , Bekaii‐Saab, Tanios , Gile, Jennifer Jane , Hubbard, Joleen , Halfdanarson, Thorvardur R , McWilliams, Robert R , Ma, Wen Wee , Ilyas, Sumera, Roberts, Lewis R , Borad, Mitesh J , Smoot, Rory L , Mahipal, Amit , Alberts, Steven R , Ou, Fang-Shu , Bekaii-Saab, Tanios S , Jin, Zhaohui , McWilliams, Robert R. , Wee, Wen , Ilyas, Sumera I. , Gores, Gregory J. , Borad, Mitesh J. , Tran, Nguyen H.

Mayo Clinic

JCO Precision Oncology | July 28, 2021 | Volume: No volume available | Issue: 5 | Pages: 1228-1240

10.1200/po.21.00064 | PMID 34778691 Get It

PURPOSECholangiocarcinomas (CCA) are a group of heterogeneous tumors arising from the biliary epithelia. Significant sequencing efforts have provided further insights into the molecular mechanisms of this disease including fibroblast growth factor receptor ( FGFR) alterations, which occurs in approximately 15%-20% of intrahepatic CCAs. Herein, we describe the FGFR inhibitor (FGFRi)-associated treatment toxicity and cancer-specific outcomes from a multicenter single-institution cohort.METHODSThis is a retrospective study of patients with CCA and known FGFR alterations treated with FGFRi. We describe the toxicity and efficacy in patients treated at Mayo Clinic between January 2010 and December 2020.RESULTSOur group identified 61 patients with advanced or metastatic CCA, 19 males (31%) and 42 females (69%), harboring FGFR alterations who received FGFRi. The most common grade 1 or higher adverse events for all patients included fatigue (92%), AST elevations (78%), anemia (80%), decreased platelet count (63%), and hyperphosphatemia (74%). Median progression-free survival on FGFRi was 5.8 months for all patients (95% CI, 4.9 to 9.0). Females had significantly longer progression-free survival at 6.9 months (95% CI, 5.2 to 11.8) on FGFRi compared with males at 4.9 months (95% CI, 2.8 to not estimable; P = .038).CONCLUSIONFGFRi are well tolerated with clinical efficacy. With the recent approval of FGFRi by the US Food and Drug Administration and ongoing clinical trials for new FGFRi, understanding outcomes and toxicity associated with these medications is important for precision oncology.
Impact of Atrial Fibrillation on Outcome in Takotsubo Syndrome: Data From the International Takotsubo Registry
El‐Battrawy, Ibrahim , Cammann, Victoria L. , Szawan, Konrad A. , Vece, Davide Di , Rossi, Aurelio, Wischnewsky, Manfred , Hermes‐Laufer, Julia , Gili, Sebastiano , Citro, Rodolfo , Franke, Jennifer , Meder, Benjamin , Knorr, Maike, Heiner, Susanne, Burgdorf, Christof , Kherad, Behrouz , Tschöpe, Carsten , Sarcon, Annahita, Shinbane, Jerold S., Rajan, Lawrence, Michels, Guido, Pfister, Roman , Cuneo, Alessandro , Jacobshagen, Claudius, Karakas, Mahir , Köenig, Wolfgang , Pott, Alexander , Meyer, Philippe , Arroja, José David , Banning, Adrian , Cuculi, Florim , Fischer, Thomas, Vasankari, Tuija , Napp, L. Christian , Budnik, Monika , Dworakowski, Rafał , MacCarthy, Philip , Osswald, Stefan , Galiuto, Leonarda , Chan, Christina , Bridgman, Paul , Beug, Daniel , Gilyarova, Ekaterina, Gilyarov, Mikhail , Kozel, Martin , Winchester, David E. , Ukena, Christian , Carrilho‐Ferreira, Pedro , Hauck, Christian , Paolini, Carla , Bilato, Claudio , Kobayashi, Yoshio, Rihal, Charanjit S. , Liu, Kan , Bianco, Matteo , Jörg, Lucas, Rickli, Hans , Böhm, Michael , Pinto, Fausto J. , Widimský, Petr , Felix, Stephan B. , Opolski, Grzegorz , Rottbauer, Wolfgang , Pieske, Burkert , Katus, Hugo A. , Münzel, Thomas , Crea, Filippo , Lüscher, Thomas F. , Duru, Fırat , Borggrefe, Martin, Ghadri, Jelena R. , Akın, İbrahim , Templin, Christian , Crea, Filippo , Citro, Rodolfo , El-Battrawy, Ibrahim , Duru, Firat , Tschöpe, Carsten , Koenig, Wolfgang , Meyer, Philippe , Banning, Adrian , Gilyarov, Mikhail , Ukena, Christian , Bilato, Claudio , Bianco, Matteo , Kato, Ken , Bossone, Eduardo , Neuhaus, Michael, Jaguszewski, Miłosz , Noutsias, Michel , D’Ascenzo, Fabrizio , Dichtl, Wolfgang , Kobza, Richard , Airaksinen, Juhani , Kaiser, Christoph A. , Delmas, Clément , Lairez, Olivier , Shilova, Alexandra S. , Toušek, Petr , Gałuszka, Jan , Poglajen, Gregor , Prasad, Abhiram , Rihal, Charanjit S. , Schulze, Paul Christian , Pestana, Gonçalo , Nguyen, Thanh Ha Tuan , Maier, Lars S. , Braun-Dullaeus, Ruediger Christian , Hasenfuß, Gerd , Schunkert, Heribert , Thiele, Hölger , Bauersachs, Johann , Horowitz, John D. , Mario, Carlo Di , Bax, Jeroen J. , Ruschitzka, Frank T.

Mayo Clinic

Journal of the American Heart Association | July 28, 2021 | Volume: 10 | Issue: 15 | Pages: No page available

10.1161/jaha.119.014059 | PMID 34315238 Get It

Background Atrial fibrillation (AF) is a major risk factor for mortality. The prevalence, clinical correlates, and prognostic impact of AF in Takotsubo syndrome (TTS) have not yet been investigated in a large patient cohort. This study aimed to investigate the prevalence, clinical correlates, and prognostic impact of AF in patients with TTS. Methods and Results Patients with TTS were enrolled from the International Takotsubo Registry, which is a multinational network with 26 participating centers in Europe and the United States. Patients were dichotomized according to the presence or absence of AF at the time of admission. Of 1584 patients with TTS, 112 (7.1%) had AF. The mean age was higher ( P <0.001), and there were fewer women ( P =0.046) in the AF than in the non‐AF group. Left ventricular ejection fraction was significantly lower ( P =0.001), and cardiogenic shock was more often observed ( P <0.001) in the AF group. Both in‐hospital ( P <0.001) and long‐term mortality ( P <0.001) were higher in the AF group. Multivariable Cox regression analysis revealed that AF was independently associated with higher long‐term mortality (hazard ratio, 2.31; 95% CI, 1.50–3.55; P <0.001). Among patients with AF on admission, 42% had no known history of AF before the acute TTS event, and such patients had comparable in‐hospital and long‐term outcomes compared with those with a history of AF. Conclusions In patients presenting with TTS, AF on admission is significantly associated with increased in‐hospital and long‐term mortality rates. Whether antiarrhythmics and/or cardioversion are beneficial in TTS with AF should thus be tested in a future trial. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01947621.
Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores
Barnes, Daniel R. , Silvestri, Valentina , Leslie, Goska , McGuffog, Lesley, Yang, Xin , Adlard, Julian , Agnarsson, Bjarni A. , Ahmed, Munaza, Aittomäki, Kristiina, Andrulis, Irene L. , Arason, Aðalgeir , Azzollini, Jacopo , Barkardóttir, Rósa B. , Barrowdale, Daniel , Belotti, Muriel, Berthet, Pascaline, Boonen, Susanne E. , Borg, Åke , Brady, Angela F., Brewer, Carole, Brunet, Joan , Bucalo, Agostino, Caldés, Trinidad , Cassingham, Hayley , Christensen, Lise Lotte , Cini, Giulia , Claes, Kathleen , Collaborators, GEMO Study, Collaborators, EMBRACE, Cortesi, Laura , Damante, Giuseppe , Darder, Esther , Davidson, Rosemarie, Leeneer, Kim De , Putter, Robin De , Valle, Jesús Del , Ding, Yuan Chun , Donaldson, Alan , Eason, Jacqueline , Eeles, Rosalind A. , Engel, Christoph , Evans, D. Gareth , Feliubadaló, Lídia , Frone, Megan N. , Frost, Debra, Gehrig, Andrea, Giraud, Sophie , Glendon, Gord , Goldgar, David E. , Greene, Mark H. , Gregory, Helen , Groß, Eva, Hahnen, Eric, Hamann, Ute, Hansen, Thomas van Overeem , Hanson, Helen , Horváth, Judit , Investigators, KConFab, Investigators, HEBON, Izatt, Louise , James, Paul A. , Janavičius, Ramūnas , Jensen, Uffe Birk , Johannsson, Oskar T., John, Esther M. , Kramer, Gero , Kroeldrup, Lone , Kruse, Torben A. , Lautrup, Charlotte Kvist , López‐Fernández, Adrià , Mai, Phuong L, Manoukian, Siranoush , Mátrai, Zoltán , Matricardi, Laura , Mebirouk, Noura, Meindl, Alfons , Montagna, Marco , Monteiro, Álvaro N.A. , Morrison, Patrick J. , Muranen, Taru , Nathanson, Katherine L. , Niederacher, Dieter , Oláh, Edith , Olopade, Olufunmilayo I. , Pedersen, Inge Søkilde , Peissel, Bernard , Peterlongo, Paolo , Petersen, Annabeth Høgh , Pinto, Pedro, Porteous, Mary, Pottinger, Caroline , Pujana, Miquel Angel, Ramser, Juliane, Rantala, Johanna, Rogers, Mark T., Rønlund, Karina, Abajo, A.M. SÁnchez De, Shah, Payal D. , Sharif, Saba , Side, Lucy, Stadler, Zsofia, Steele, Linda , Sutter, Christian , Tan, Yen Y. , Teixeira, Manuel R. , Teulé, Àlex , Thull, Darcy L. , Trainer, Alison H., Tripathi, Vishakha , Valentini, Virginia , Viel, Alessandra , Walker, Lisa, Wang‐Gohrke, Shan , Wappenschmidt, Barbara , Whaite, Anna , Offit, Kenneth, Thomassen, Mads , Schmutzler, Rita K., Simard, Jacques , Easton, Douglas F. , Chenevix‐Trench, Georgia , Antoniou, Antonis C. , Pujana, Miguel Ángel , Dennis, Joe , Yang, Xin , Adlard, Julian , Agnarsson, Bjarni A , Andrulis, Irene L , Arason, Adalgeir , Arnold, Norbert , Auber, Bernd , Azzollini, Jacopo , Barkardottir, Rosa B , Barrowdale, Daniel , Benitez, Javier , Boonen, Susanne E , Bozsik, Aniko , Brennan, Paul , Brunet, Joan , Bucalo, Agostino , Caligo, Maria A , Campbell, Ian G , Cassingham, Hayley , Cini, Giulia , Claes, Kathleen B M , Coppa, Anna , Cortesi, Laura , Darder, Esther , de la Hoya, Miguel , de Putter, Robin , Del Valle, Jesús , Domchek, Susan M , Donaldson, Alan , Eason, Jacqueline , Engel, Christoph , Fostira, Florentia , Frone, Megan , Glendon, Gord , Godwin, Andrew K. , Greene, Mark H , Hahnen, Eric , Hanson, Helen , Izatt, Louise , Izquierdo, Angel , James, Paul , John, Esther M , Kroeldrup, Lone , Kruse, Torben A , Lazaro, Conxi , Lesueur, Fabienne , Matrai, Zoltan , Montagna, Marco , Monteiro, Alvaro N , Morrison, Patrick J , Muranen, Taru A , Nathanson, Katherine L , Neuhausen, Susan L. , Nevanlinna, H , Nguyen-Dumont, Tu , Niederacher, Dieter , Palli, Domenico , Parsons, Michael T , Perez-Segura, Pedro , Peterlongo, Paolo , Pinto, Pedro , Pottinger, Caroline , Radice, Paolo , Robson, Mark , Rump, Andreas , Sharif, Saba , Steele, Linda , Stoppa-Lyonnet, Dominique , Teixeira, Manuel R , Thull, Darcy L , Tischkowitz, Marc D. , Toland, Amanda Ewart , Tommasi, Stefania , Toss, Angela , Tripathi, Vishakha , Valentini, Virginia , van Asperen, Christi J , Venturelli, Marta , Viel, Alessandra , Joseph, Vijai , Whaite, Anna , Simard, Jacques , Easton, Doug , Chenevix-Trench, Georgia , Ottini, Laura , Barnes, Daniel R , Leslie, Goska , Pujana, Miquel Angel , Eeles, Rosalind A , Evans, D Gareth , Matricardi, Laura , Olopade, Olufunmilayo I , Silvestri, Valentina , De Leeneer, Kim , Feliubadaló, Lidia , Hansen, Thomas van Overeem , Manoukian, Siranoush , Arnold, Norbert , Auber, Bernd , Balmañà, Judith , Barwell, Julian , Benı́tez, Javier , Bozsik, Anikó , Brady, Angela F., Buys, Saundra S. , Caligo, Maria A. , Campbell, Ian , Collaborators, GEMO Study, Collaborators, EMBRACE, Cook, Jackie A , Hoya, Miguel de la , Dı́ez, Orland , Domchek, Susan M. , Gallagher, David James , Hentschel, Julia , Investigators, KConFab, Investigators, HEBON, Izquierdo, Á. , Lázaro, Conxi , Lesueur, Fabienne , Mai, Phuong L, Maxwell, Kara N. , Meindl, Alfons , Nevanlinna, Heli , Nguyen‐Dumont, Tú , Palli, Domenico , Parsons, Michael T. , Radice, Paolo , Robson, Mark E. , Rump, Andreas , Singer, Christian F. , Stoppa‐Lyonnet, Dominique , Asperen, Christi J. van , Vijai, Joseph , Zanna, Ines , Couch, Fergus J. , Ottini, Laura

Mayo Clinic

JNCI: Journal of the National Cancer Institute | July 26, 2021 | Volume: 114 | Issue: 1 | Pages: 109-122

10.1093/jnci/djab147 | PMID 34320204 Get It

AbstractBackgroundRecent population-based female breast cancer and prostate cancer polygenic risk scores (PRS) have been developed. We assessed the associations of these PRS with breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers.Methods483 BRCA1 and 1318 BRCA2 European ancestry male carriers were available from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). A 147-single nucleotide polymorphism (SNP) prostate cancer PRS (PRSPC) and a 313-SNP breast cancer PRS were evaluated. There were 3 versions of the breast cancer PRS, optimized to predict overall (PRSBC), estrogen receptor (ER)–negative (PRSER-), or ER-positive (PRSER+) breast cancer risk.ResultsPRSER+ yielded the strongest association with breast cancer risk. The odds ratios (ORs) per PRSER+ standard deviation estimates were 1.40 (95% confidence interval [CI] =1.07 to 1.83) for BRCA1 and 1.33 (95% CI = 1.16 to 1.52) for BRCA2 carriers. PRSPC was associated with prostate cancer risk for BRCA1 (OR = 1.73, 95% CI = 1.28 to 2.33) and BRCA2 (OR = 1.60, 95% CI = 1.34 to 1.91) carriers. The estimated breast cancer odds ratios were larger after adjusting for female relative breast cancer family history. By age 85 years, for BRCA2 carriers, the breast cancer risk varied from 7.7% to 18.4% and prostate cancer risk from 34.1% to 87.6% between the 5th and 95th percentiles of the PRS distributions.ConclusionsPopulation-based prostate and female breast cancer PRS are associated with a wide range of absolute breast and prostate cancer risks for male BRCA1 and BRCA2 carriers. These findings warrant further investigation aimed at providing personalized cancer risks for male carriers and informing clinical management.
Abstract 14735: Carotid Artery Stenting and Carotid Endarterectomy are Comparable Among Medicare Beneficiaries Treated in Routine Clinical Practice
Jalbert, Jessica J. , Nguyen, Louis L. , Gerhard‐Herman, Marie , Williams, Lauren , Chen, Chih‐Ying , Liu, Jun , Rothman, Andrew, Seeger, John D. , Benenati, James F., Schneider, Peter A. , Brott, Thomas G. , Tsai, Thomas T., Setoguchi, Soko , Kumamaru, Hiraku , Jaff, Michael R. , Aronow, Herbert D. , Johnston, Joseph A. , White, Christopher J.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 130 | Issue: suppl_2 | Pages: No page available

10.1161/circ.130.suppl_2.14735 Get It

Introduction: The relative performance of carotid artery stenting (CAS) and carotid endarterectomy (CEA) among Medicare beneficiaries in routine clinical practice has not been established. Objective: To compare the performance of CAS relative to CEA among Medicare beneficiaries. Methods: We linked Medicare data (2000-2009) to the Society for Vascular Surgery’s Vascular Registry (SVS-VR; 2005-2008) and to the NCDR® Carotid Artery Revascularization and Endarterectomy Registry (CARE; 2006-2008/9). Medicare patients aged ≥66 years undergoing CAS or CEA were followed from the procedure date for the outcomes of death, stroke/transient ischemic attack (TIA), peri-procedural myocardial infarction (MI) or a composite endpoint for these outcomes. We derived high-dimensional propensity scores using registry and Medicare data to control for patient-level factors and adjusted for provider-level factors including past-year CAS/CEA physician and hospital volume, hospital ownership, teaching affiliation, and hospital size in a Cox regression model comparing CAS to CEA. Results: Among 5,254 SVS-VR (1,999 CAS and 3,255 CEA) and 4,055 CARE (2,824 CAS and 1,231 CEA) patients, CAS patients were more often at higher surgical risk (SVS-VR: 96.7% vs. 44.5%; CARE: 71.3% vs. 44.7%) and had a higher comorbidity burden. Crude outcome risks for death and stroke/TIA were lower for CEA. Adjusting for patient-level factors drove estimates downwards for CAS relative to CEA but only after further adjustment for provider-level factors did the performance of CAS and CEA become comparable on all outcomes (figure 1). Conclusion: Performance of CAS and CEA among Medicare beneficiaries was comparable after accounting for patient- and provider-level factors, which is consistent with landmark trials. Further studies are needed to understand the role of heterogeneity in provider-level characteristics.
Updates in the management of relapsed/refractory multiple myeloma
Hanna, Kirollos S. , Larson, Samantha, Tu, Sarah, Boudreau, Jenna, Rose, Sarah, Nguyen, Jenny , Rose, Sarah

Mayo Clinic

Journal of Oncology Pharmacy Practice | June 24, 2021 | Volume: 27 | Issue: 6 | Pages: 1477-1490

10.1177/10781552211028906 | PMID 34162244 Get It

Multiple myeloma, a malignant neoplasm of plasma cells that accumulate in bone marrow, accounts for approximately 18% of hematologic malignancies in the United States. Patients are often treated with triplet therapy and may undergo stem cell transplantation. Despite effective therapies, multiple myeloma remains incurable. Patients often require maintenance therapy, and many will progress or relapsed following upfront treatment. Selection of treatment in the relapse/refractory setting is complex due numerous active therapeutic agents and combinations. Treatment is often tailored to prior exposure and duration. In 2020, three novel pharmacological agents were approved in the relapsed setting. We highlight the clinical safety and efficacy of selinexor, isatuximab-irfc, and belantamab mafodotin for patients with multiple myeloma.
Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer
Quinn, Michael C. , McCue, Karen, Shi, Wei , Johnatty, Sharon E. , Beesley, Jonathan, Civitarese, Andrew, O’Mara, Tracy A. , Glubb, Dylan M. , Armasu, Sebastian M. , Ong, Jue‐Sheng , Lu, Yi , Gao, Bo , Patch, Ann‐Marie , Fasching, Peter A. , Beckmann, Matthias W. , Lambrechts, Diether , Vergote, Ignace , Beeghly‐Fadiel, Alicia, García, María J. , Goodman, Marc T. , Dörk, Thilo , Moysich, Kirsten B. , Pfisterer, Jacobus , Bauman, Klaus, Lester, Jenny , Cunningham, Julie M. , McCauley, Bryan M. , Høgdall, Claus , Schildkraut, Joellen M. , Riggan, Marjorie J. , Terry, Kathryn L. , Webb, Penelope M. , May, Taymaa, Ene, Gabrielle, Huntsman, David G., Woo, Michelle, Carney, Michael E. , Fereday, Sián , Kennedy, Catherine J. , Edwards, Stacey L. , DeFazio, Anna , Goode, Ellen L. , MacGregor, Stuart , Chenevix‐Trench, Georgia , Lambrechts, Diether , Quinn, Michael C J , Ong, Jue-Sheng , Gharahkhani, Puya , Lu, Yi , Fasching, Peter A , Lambrechts, Diether , Vergote, Ignace , Dörk, Thilo , Dürst, Matthias , Modugno, Francesmary , Bois, Andreas du , Karlan, Beth Y , Cunningham, Julie M , Kjaer, Susanne K , Webb, Penelope M , Friedlander, Michael , Glasspool, Rosalind , Hinsley, Samantha , Heitz, Florian , Kennedy, Catherine J , Winham, Stacey J , Fazio, Anna de , Pharoah, Paul D P , MacGregor, Stuart , Lambrechts, Diether , Moysich, Kirsten , O'Mara, Tracy A , Chenevix-Trench, Georgia , Høgdall, Claus K , Fereday, Sian , Goodman, Marc T , Beesley, Jonathan, Tyrer, Jonathan P. , Gharahkhani, Puya , Edwards, Digna R. Velez , Beeghly‐Fadiel, Alicia , Benı́tez, Javier , Modugno, Francesmary , Karlan, Beth Y. , Larson, Melissa C. , Kjær, Susanne K. , Jensen, Allan , Høgdall, Estrid , Berchuck, Andrew , Cramer, Daniel W. , Bjørge, Line , Friedländer, Michael , Pejovic, Tanja B. , Moffitt, Melissa , Glasspool, Rosalind , Heitz, Florian , Winham, Stacey J. , Pharoah, Paul D.P.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 23, 2021 | Volume: 30 | Issue: 9 | Pages: 1669-1680

10.1158/1055-9965.epi-20-1817 | PMID 34162658 Get It

Abstract Background: Many loci have been found to be associated with risk of epithelial ovarian cancer (EOC). However, although there is considerable variation in progression-free survival (PFS), no loci have been found to be associated with outcome at genome-wide levels of significance. Methods: We carried out a genome-wide association study (GWAS) of PFS in 2,352 women with EOC who had undergone cytoreductive surgery and standard carboplatin/paclitaxel chemotherapy. Results: We found seven SNPs at 12q24.33 associated with PFS (P &lt; 5 × 10–8), the top SNP being rs10794418 (HR = 1.24; 95% CI, 1.15–1.34; P = 1.47 × 10–8). High expression of a nearby gene, ULK1, is associated with shorter PFS in EOC, and with poor prognosis in other cancers. SNP rs10794418 is also associated with expression of ULK1 in ovarian tumors, with the allele associated with shorter PFS being associated with higher expression, and chromatin interactions were detected between the ULK1 promoter and associated SNPs in serous and endometrioid EOC cell lines. ULK1 knockout ovarian cancer cell lines showed significantly increased sensitivity to carboplatin in vitro. Conclusions: The locus at 12q24.33 represents one of the first genome-wide significant loci for survival for any cancer. ULK1 is a plausible candidate for the target of this association. Impact: This finding provides insight into genetic markers associated with EOC outcome and potential treatment options. See related commentary by Peres and Monteiro, p. 1604
Intranodal Sirolimus Induces Regulatory T Cells in Human Hepatic Lymph Nodes via Interleukin 10 Signaling
Nguyen, Justin H. , Jiang, Liuyan , Lu, Kang , Malik, Sunita , Orlando, Christopher , Rehman, Fatima , Kang, Lu, Malik, Sunita, Zubair, Abba C.

Mayo Clinic

Liver Transplantation | June 16, 2021 | Volume: 27 | Issue: 11 | Pages: 1669-1672

10.1002/lt.26214 | PMID 34133835 Get It

Defects in DNA Ligase I Trigger PCNA Ubiquitination at Lysine 107
Das‐Bradoo, Sapna, Ricke, Robin M., Haworth, Justin, Nguyen, Hai Dang , Bielinsky, Anja‐Katrin

Mayo Clinic

The FASEB Journal | June 15, 2021 | Volume: 24 | Issue: S1 | Pages: No page available

10.1096/fasebj.24.1_supplement.492.5 Get It

The anti‐parallel nature of DNA permits continuous synthesis of DNA on the leading strand and discontinuous DNA synthesis on the lagging strand. On the lagging strand, Okazaki fragments are joined by the catalytic action of DNA ligase I. An individual with a DNA ligase I deficiency exhibited growth retardation, sunlight sensitivity and severe immunosuppression, likely due to accumulation of DNA damage. Surprisingly, little is known about the DNA damage response (DDR) in DNA ligase I‐deficient cells. We utilized Saccharomyces cerevisiae as a model system to address this question. We uncovered a novel pathway, which facilitates ubiquitination of proliferating cell nuclear antigen (PCNA) on lysine 107. Unlike PCNA ubiquitination at lysine 164 in response to UV irradiation, which triggers translesion synthesis and is dependent on Rad6 and Rad18, modification at lysine 107 requires the E2 variant Mms2 in conjunction with Ubc4 and Rad5. Surprisingly, DNA ligase I‐deficient cdc9‐1 cells that carry a PCNAK107R mutation are inviable, because they cannot activate a robust DDR. Our data show that depending on the type of damage that a cell encounters, PCNA is ubiquitinated at different lysine residues. We propose a “DNA Damage code” that allows cells to recognize different types of DNA damage through differential PCNA ubiquitination, allowing the cells to activate the appropriate repair response.
Cardiac surgeons' concerns, perceptions, and responses during the COVID‐19 pandemic
Luc, Jessica G.Y. , Ad, Niv , Nguyen, Tom C. , Collaborators, the COVID‐19 North American Cardiac Surgery Survey Working Group, Arora, Rakesh C. , Bender, Edward M. , Bethencourt, Daniel M., Bisleri, Gianluigi , Boyd, Douglas, Chu, Michael , Cruz, Kim I. de la , DeAnda, Abe , Farkas, Emily A. , Fedoruk, Lynn M., Fiocco, Michael, Forcillo, Jessica , Fradet, Guy, Gammie, James S. , Geirsson, Arnar , Gerdisch, Marc , Girard, Leonard N., Kaiser, Clayton A., Khabbaz, Kamal R. , Khoynezhad, Ali , Kiaii, Bob, Légaré, Jean‐François , Lehr, Eric J. , MacArthur, Roderick, McCarthy, Patrick M. , Mehall, John R., Merrill, Walter H. , Moon, Marc R. , Ouzounian, Maral , Peltz, Matthias , Perrault, Louis P. , Preventza, Ourania , Ramchandani, Mahesh, Ramlawi, Basel , Salenger, Rawn , Sekela, Michael , Stulak, John M., Sutter, Francis P., Timek, Tomasz A. , Whitman, Glenn, Williams, Judson B., Yanagawa, Bobby , Ye, Jian , Zeigler, Sanford , Bisleri, Gianluigi , Forcillo, Jessica , Fremes, Stephen E , Geirsson, Arnar , Gerdisch, Marc W , Girard, Leonard N , Legare, Jean-Francois , Moon, Marc R , Preventza, Ourania , Yanagawa, Bobby , Ye, Jian , Arora, Rakesh , Chu, Michael W A , Collaborators, the COVID‐19 North American Cardiac Surgery Survey Working Group, Balkhy, Husam H. , Boyd, Douglas, Engelman, Daniel T. , Fremes, Stephen E. , Kaneko, Tsuyoshi , Kent, William D. T. , Lee, Richard , Sellke, Frank W. , Wong, Daniel R.

Mayo Clinic

Journal of Cardiac Surgery | June 12, 2021 | Volume: 36 | Issue: 9 | Pages: 3040-3051

10.1111/jocs.15681 | PMID 34118080 Get It